Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMPHOTEC vs ANCOBON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Treatment of progressive, potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis,Treatment of visceral leishmaniasis (off-label),Empiric therapy in febrile neutropenic patients (off-label),Treatment of primary amebic meningoencephalitis (off-label)
Treatment of systemic fungal infections (e.g., candidiasis, cryptococcosis) in combination with amphotericin B,Off-label: Serious infections caused by susceptible fungi
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (Cr Cl < 20 m L/min). Half-life correlates with creatinine clearance.
Metabolized minimally, if at all; elimination is primarily via unchanged drug excretion in urine and bile over a prolonged period.
Deaminated to 5-fluorouracil in the body; further metabolized via same pathways as fluorouracil.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
>95% bound to albumin and alpha-1-acid glycoprotein.
2-4% bound to plasma proteins (albumin).
4.0 L/kg (large, indicates extensive tissue binding, especially in liver, spleen, and lungs).
0.6-0.9 L/kg, indicating distribution into total body water. Penetrates well into cerebrospinal fluid (50-100% of serum levels), aqueous humor, and peritoneal fluid.
Not applicable (IV only); if oral, <5% (due to poor absorption and first-pass metabolism).
Oral: 76-89% (well absorbed).
No dose adjustment required for renal impairment; however, monitor renal function closely during therapy.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: 50-100 mg/kg/day divided every 12-24 hours; GFR <10 m L/min: 50-100 mg/kg/day every 24-48 hours; intermittent hemodialysis: 50-100 mg/kg/day with each dialysis session; peritoneal dialysis: 50-100 mg/kg/day every 48 hours.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
No specific pediatric dosing based on Child-Pugh; use with caution and monitor liver function, potential reduced clearance. No standard adjustment defined.
5 mg/kg intravenously once daily; safety and efficacy not established in neonates.
Weight-based: 50-150 mg/kg/day orally divided every 6 hours, or 50-150 mg/kg/day intravenously divided every 12 hours; neonates: 25-100 mg/kg/day intravenously divided every 12 hours.
No specific dose adjustment; monitor renal function and electrolyte levels due to age-related decline in renal function.
Start at lower end of dosing range (50 mg/kg/day), adjust based on renal function; monitor for hematologic toxicity.
This drug should be used primarily for treatment of patients with progressive, potentially life-threatening fungal infections; it is not intended for treatment of non-invasive fungal infections (e.g., oral thrush, vaginal candidiasis) in patients with normal neutrophil counts.
None.
Nephrotoxicity: monitor renal function closely; risk increased with concurrent nephrotoxic drugs.,Infusion-related reactions: fever, chills, rigors, hypotension, dyspnea; premedicate as needed.,Electrolyte abnormalities: hypokalemia, hypomagnesemia; monitor levels and replace.,Hepatotoxicity: monitor liver function tests.,Cardiotoxicity: arrhythmias, especially with rapid infusion or hypokalemia.,Pulmonary toxicity: acute pulmonary edema (rare), especially in patients with low ejection fraction.
Hematologic toxicity (leukopenia, thrombocytopenia); renal impairment requires dose adjustment; hepatotoxicity; monitoring of blood counts and renal function recommended.
Hypersensitivity to amphotericin B or any component of the formulation (unless condition is life-threatening and amenable only to amphotericin therapy).
Hypersensitivity to flucytosine or any component.
No specific food interactions. Ensure adequate hydration and electrolyte intake as directed. Avoid grapefruit juice as it may alter drug metabolism.
May be taken with food to reduce gastrointestinal upset. No specific dietary restrictions. Avoid alcohol.
Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use during the first trimester is not associated with a significant increase in congenital anomalies. During the second and third trimesters, there is no evidence of fetal toxicity, although the drug should be used only if clearly needed due to maternal systemic fungal infection.
Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly needed. Potential fetal risk in all trimesters. Contraindicated in first trimester unless life-threatening maternal infection.
Amphotericin B is excreted into breast milk in low concentrations. The M/P ratio is unknown. It is considered compatible with breastfeeding because of poor oral bioavailability; however, caution is advised, and monitoring for infant diarrhea or thrush is recommended.
Flucytosine is excreted into human breast milk; milk-to-plasma ratio approximately 1.0. Potential for serious adverse reactions in nursing infants; decision to discontinue nursing or drug depends on importance of drug to mother.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustment. Standard dosing is 3-5 mg/kg/day IV, but serum concentrations should be monitored to ensure therapeutic levels without excessive toxicity. Dose may need to be increased by 25-50% in the third trimester.
Pregnancy may alter pharmacokinetics due to increased renal clearance and expanded plasma volume. Dose adjustment may be necessary; maintain serum concentrations within therapeutic range (trough 20-50 mcg/m L). Reduce dose in renal impairment, which may occur in pregnancy. No specific pregnancy dose guidelines; use with caution and monitor levels.
Amphotec (amphotericin B liposomal) is the preferred formulation for invasive fungal infections due to reduced nephrotoxicity compared to deoxycholate. Monitor for infusion-related reactions (fever, rigors, hypotension) and premedicate with acetaminophen, diphenhydramine, and hydrocortisone. Requires baseline and serial renal function, electrolytes (especially potassium, magnesium), and liver function tests. Do not use with other nephrotoxic drugs if possible. Electrolyte repletion is critical.
Monitor for hepatotoxicity and bone marrow suppression; adjust dose in renal impairment (Cr Cl <50 m L/min requires dose interval extension). Obtain serum levels (desired peak 50-100 mcg/m L, trough <50 mcg/m L) to avoid toxicity. Use with caution in patients with pre-existing hematologic disorders or hepatic dysfunction. Synergistic with amphotericin B for cryptococcal meningitis; avoid concurrent use with nucleoside analogues (e.g., cytarabine) due to antagonism.
This medication treats serious fungal infections and is given intravenously in a hospital setting.,You may experience fever, chills, or shaking during the infusion; these can be managed with premedications.,Kidney function and blood electrolyte levels will be monitored regularly.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or symptoms of electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,Avoid taking other medications that can harm the kidneys (e.g., certain antibiotics, NSAIDs) without consulting your doctor.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,May cause nausea and vomiting; taking with food can help.,Report any signs of liver problems (yellowing skin/eyes, dark urine, severe abdominal pain) or unusual bruising/bleeding immediately.,Avoid alcohol while on this medication.,Use effective contraception during treatment; notify your doctor if you become pregnant.,Regular blood tests are required to monitor blood counts and liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMPHOTEC vs ANCOBON, answered by our medical review team.
AMPHOTEC is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.. ANCOBON is a Antifungal that works by Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMPHOTEC and ANCOBON depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMPHOTEC is: Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.. The standard adult dose of ANCOBON is: 50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMPHOTEC and ANCOBON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMPHOTEC is classified as Category C. Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use d. ANCOBON is classified as Category C. Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly nee. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.